Moderna announced IND Submitted to FDA for phase 2 study of mRNA vaccine (mRNA-1273) against novel Coronavirus
On Apr. 27, 2020, Moderna announced it had submitted an Investigational New Drug application to the U.S. Food…
Researchers identified cells likely targeted by COVID-19 virus
On Apr. 22, 2020, researchers at Massachusetts Institute of Technology (MIT); the Ragon Institute of MGH, and Harvard…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Therapeutics | Vaccine
Biogen, Broad Institute of MIT and Harvard, Partners HealthCare launched consortium to build and share a COVID-19 Biobank
On Apr. 16, 2020, Biogen, Broad Institute of MIT and Harvard, and Partners HealthCare announced a consortium that…
Moderna announced BARDA award for up to $483 million to accelerate development of mRNA vaccine (mRNA-1273) against novel Coronavirus
On Apr. 16, 2020, Moderna announced an agreement for a commitment of up to $483 million from the…
Biogen, Broad Institute of MIT and Harvard, Partners HealthCare consortium build and share COVID-19 biobank
On Apr. 16, 2020, a team of researchers at the McGovern Institute for Brain Research at MIT, the…
Harvard, MIT and Stanford commited to COVID-19 technology licensing principles, maximizing access to innovations
On Apr. 7, 2020, Harvard University, Massachusetts Institute of Technology, and Stanford University announced they had established and…
New antiviral drug from Emory University heading into clinical trials for COVID-19 treatment
On Apr. 6, 2020, Emory’s Vaccine and Treatment Evaluation Unit (VTEU) announced its participation in a clinical trial…
New IHME COVID-19 forecasts find lower hospital bed need, epidemics starting to peak confirms social distancing works
On Apr. 5, 2020, updated COVID-19 estimates from the Institute for Health Metrics and Evaluation (IHME) found that…
BioAegis accelerated multiple clinical trial submissions for severe COVID-19 pneumonia patients
On Apr. 2, 2020, BioAegis Therapeutics announced that it was preparing to evaluate plasma gelsolin replacement in severe…
Broad Institute’s CLIA-certified testing center began processing COVID-19 patient samples
On Mar. 26, 2020, working in partnership with the Commonwealth of Massachusetts, Massachusetts State Public Health Laboratory, and…
Oxford University COVID-19 study showed that Wuhan travel restrictions prevented wider disease spread
On Mar. 25, 2020, a mobility and epidemiological study from a global consortium of researchers, led by the…
The Simmons Cancer Center joined elite National Comprehensive Cancer Network
On Mar. 24, 2020, the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern announced it had joined…
The Priestley Medal was awarded to JoAnne Stubbe
On Mar. 23 2020, The Priestley Medal was awarded to JoAnne Stubbe by the American Chemical Society “to…
Harvard Bioscience introduced next generation inhalation system to aid in fight against COVID-19
On Mar. 23, 2020, Harvard Bioscience announced that it had launched an innovative technology – known as Accumulated…
Moderna announced first participant dosed in NIH-led phase 1 study of mRNA vaccine against novel Coronavirus
On Mar. 16, 2020, Moderna announced that the first participant had been dosed in the Phase 1 study…
Moderna completed enrollment of Cytomegalovirus vaccine (mRNA-1647) phase 2 study
On Mar. 3, 2020, Moderna announced that enrollment was complete for all three dose cohorts of the Phase…
Biotechnology | COVID-19 | Diagnostics | Life Science History | Non-Profit Research | Therapeutics | Vaccine
Boston University NEIDL scientists joined international Coronavirus research effort
On Mar. 2, 2020, Boston’s top infectious disease researchers, including scientists from Boston University’s National Emerging Infectious Diseases…
Innovation Pharma provided scientific rationale and clinical development perspectives for Brilacidin as potential Coronavirus treatment
On Mar. 2, 2020, Innovation Pharma provided the scientific rationale and clinical development perspectives for Brilacidin, the Company’s…
Moderna shipped mRNA vaccine against novel Coronavirus (mRNA-1273) for phase 1 study
On Feb. 24, 2020, Moderna announced it had released the first batch of mRNA-1273, the Company’s vaccine against…
Artificial intelligence yielded new antibiotic
On Feb. 20, 2020, using a machine-learning algorithm, researchers at MIT and the Broad Institute of MIT and…
Moderna announced funding award from CEPI to accelerate development of mRNA vaccine against novel Coronavirus
On Jan. 23, 2020, Moderna announced a new collaboration to develop an mRNA vaccine against the novel coronavirus…
Novo Ventures and the Broad Institute of MIT and Harvard announced the launch of the Novo Broad Greenhouse
On Nov. 19, 2019, Novo Ventures and the Broad Institute of MIT and Harvard announced the launch of…
Vanderbilt Vaccine Center Director James Crow Jr, MD, was awarded half of the Future Insight Prize by Merck KGaA of Germany
On Jul. 9, 2019, Vanderbilt Vaccine Center announced that Director James Crow Jr., MD, had been awarded half…
FUJIFILM opened Life Science Strategic Business Office in Cambridge, Massachusetts
On May 30, 2019, FUJIFILM opened a Life Science Strategic Business Office in Cambridge, Massachusetts to create a…
Massachusetts General Hospital received $200 million to advance research into complex diseases
On Apr. 29, 2019, Massachusetts General Hospital (MGH) announced it had received the largest gift in the hospital’s…
ICON acquired MolecularMD
On Feb. 21, 2019, ICON announced that it had acquired MolecularMD, a molecular diagnostic specialty laboratory that enables…
TESARO was acquired by GSK for $5.1 billion
On Jan. 22, 2019, GlaxoSmithKline acquired TESARO based in Waltham, Massachusetts, for an aggregate cash consideration of approximately…
Takeda Pharmaceutical acquired Shire
On Jan. 8, 2019, Takeda Pharmaceutical announced the completion of its acquisition of Lexington, Massachusetts-based Shire for a…
AquAdvantage announced FDA approval of first U.S. facility for commercial production of AquAdvantage Salmon
On Apr. 27, 2018, AquaBounty Technologies announced that it had received approval from the U.S. Food and Drug…
Sanofi acquired Bioverativ for $11.6 billion
On Mar. 8, 2018, Sanofi acquired Waltham, Massachusetts-based Bioverativ for for $11.6 billion. Bioverativ’s extended half-life therapies, Eloctate…